Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs

被引：0
作者：
Hidekatsu Nakai
Noriomi Matsumura
机构：
[1] Kindai University,Department of Obstetrics and Gynecology, Faculty of Medicine
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Ovarian cancer; Molecularly targeted drug; PARP inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With the development of poly(ADP-ribose) polymerase inhibitors, the treatment of advanced ovarian cancer is changing dramatically. The purpose of this narrative review is to provide a direction for the individualization of advanced ovarian cancer treatment based on the mechanism of action of molecularly targeted drugs currently used in Japan. The PAOLA-1 study showed very good progression-free survival in patients with homologous recombination deficiency tumors who underwent complete surgery with primary debulking surgery and who received olaparib plus bevacizumab. Niraparib has high intratumor penetration, and in a subgroup analysis of the PRIMA study, it was most effective in patients with residual tumors after interval debulking surgery. These data suggest the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized.
引用
收藏
页码：1001 / 1012
页数：11
相关论文
共 133 条
[1]  
Li H(2021)Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results N Engl J Med 384 497-511
[2]  
Liu ZY(2020)PARP inhibitor resistance: the underlying mechanisms and clinical implications Mol Cancer 19 107-5599
[3]  
Wu N(2012)Trapping of PARP1 and PARP2 by Clinical PARP inhibitors Cancer Res 72 5588-1477
[4]  
Murai J(2015)Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol Cancer Res 13 1465-37096
[5]  
Huang SN(2020)Structural basis for allosteric PARP-1 retention on DNA breaks Science 368 eaax6367-494
[6]  
Das BB(2018)A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Oncotarget 9 37080-4133
[7]  
Hopkins TA(2015)Whole-genome characterization of chemoresistant ovarian cancer Nature 521 489-441
[8]  
Shi Y(2013)P-glycoprotein ABCB1: a major player in drug handling by mammals J Clin Invest 123 4131-827
[9]  
Rodriguez LE(2016)ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells Br J Cancer 115 431-2973
[10]  
Zandarashvili L(2021)Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report Ann Palliat Med 10 818-1731
12345678910